Literature DB >> 16638557

Mechanical devices and US Food and Drug Administration (FDA) approval.

Bruce A Reitz1.   

Abstract

Long-term ventricular assist devices for adults have advanced far more than have suitable devices for neonates and infants. The difficulties of design and construction of miniaturized blood pumping systems and the high costs associated with developing, testing, and approval of such devices has been prohibitive. Still, there is an important clinical need for such devices as the availability of donor hearts for this age group has been especially limited. Recently, several pneumatic pulsatile pumps have been developed based on the adult experience, and the issues of regulatory approval are now assuming greater importance for these devices. This chapter reviews the current system for medical device classification and the approval processes in the United States and in Europe. This system is continually evolving, with dedicated and knowledgeable professionals charged with assuring the efficacy, safety, appropriate labeling, and continuing surveillance of approved devices. Pediatric cardiac surgeons involved in transplantation and assist devices need to be aware of the regulatory issues, and work with manufacturers and governmental agencies to make sure that successful devices are available as soon as possible for their patients.

Entities:  

Mesh:

Year:  2006        PMID: 16638557     DOI: 10.1053/j.pcsu.2006.02.018

Source DB:  PubMed          Journal:  Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu        ISSN: 1092-9126


  2 in total

1.  The future of adult cardiac assist devices: novel systems and mechanical circulatory support strategies.

Authors:  Carlo R Bartoli; Robert D Dowling
Journal:  Cardiol Clin       Date:  2011-11       Impact factor: 2.213

2.  Comparison of supportive regulatory measures for pediatric medical device development in Japan and the United States.

Authors:  Sara Takahashi; Kiyotaka Iwasaki; Haruki Shirato; Mami Ho; Mitsuo Umezu
Journal:  J Artif Organs       Date:  2020-10-20       Impact factor: 1.731

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.